TY  - JOUR
T1  - Peptide receptor radionuclide therapy with lutetium-177 DOTATATE in a case of recurrent extradrenal retroperitoneal malignant paraganglioma with nodal and bone metastasis
A1  - Koramadai Kamaleshwaran
A1  - Paulvannan Subramaniam
A1  - Sudhakar Natarajan
A1  - Pavanasam Velayutham
A1  - Vyshak Mohanan
A1  - Ajit Shinto
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2015
VL  - 4
IS  - 1
DO  - 10.4103/2278-0513.149058
SP  - 84
EP  - 87
N2  - Extra-adrenal retroperitoneal paragangliomas (PGLs) are rare tumors causing considerable difficulty in both, diagnosis and treatment. They can be unicentric or multicentric, tend to be locally invasive and therefore have a high incidence of local recurrence. PGLs shows somatostatin receptor positivity, which can be imaged with technetium-99m (Tc-99m)-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) and can be treated with lutetium-177 (Lu-177) DOTATATE. We present a case of recurrent unresectable retroperitoneal PGL with nodal and bone metastases in a 27-year-old male, 6 months postsurgery detected with Tc-99m-HYNIC-TOC and was administered with peptide receptor radionuclide therapy using Lu-177 DOTATATE.
UR  - https://ccij-online.org/article/peptide-receptor-radionuclide-therapy-with-lutetium-177-dotatate-in-a-case-of-recurrent-extradrenal-retroperitoneal-malignant-paraganglioma-with-nodal-and-bone-metastasis-328
ER  -